FDA issues Class II recall of two lots of blood pressure tablets
The FDA has classified a recall of two lots of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide tablets as a Class II recall after dissolution failures were identified.
The U.S. Food and Drug Administration announced a Class II recall of two nationwide-distributed lots of a combination blood pressure medication containing Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide. The recall, which covers 3,528 bottles of 30 tablets and 216 bottles of 90 tablets, was upgraded to Class II on Oct. 26 after the products failed to meet dissolution specifications.
The affected lots are identified as 2251163A and 12251163B, both with an expiration date of May 31, 2027. The medication, described by the Mayo Clinic as a combination that can be used alone or with other agents to treat hypertension, includes an angiotensin II receptor blocker, a calcium-channel blocker and a diuretic.
"A Class II recall is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote," the FDA explained.
Patients who have been prescribed the recalled tablets are advised to check their medication bottles and consult their healthcare providers for alternatives.